Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma

PURPOSE: In the Phase III SIROCCO trial (NCT01928771), benralizumab significantly reduced asthma exacerbations and improved lung function and symptoms for patients with severe, uncontrolled eosinophilic asthma. The aim of this subgroup analysis was to evaluate efficacy and safety of benralizumab for...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hae-Sim, Lee, Sang Haak, Lee, Sook Young, Kim, Mi-Kyeong, Lee, Byung Jae, Werkström, Viktoria, Barker, Peter, Zangrilli, James G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557768/
https://www.ncbi.nlm.nih.gov/pubmed/31172719
http://dx.doi.org/10.4168/aair.2019.11.4.508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557768/
https://www.ncbi.nlm.nih.gov/pubmed/31172719
http://dx.doi.org/10.4168/aair.2019.11.4.508

Ejemplares similares